CAPR News and Press, Capricor Therapeutics Inc. From 03/23/23

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...

2023-03-15 18:32:04 ET Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Conference Call March 15, 2023 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Michael Oku...

2023-03-15 16:03:53 ET Capricor Therapeutics press release ( NASDAQ: CAPR ): Q4 GAAP EPS of -$0.31 beats by $0.03 . Revenue of $0.96M beats by $0.96M . The Company’s cash, cash equivalents and marketable securities totaled approximately $41.4 million as ...

-Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); Plan to Report on Interim Analysis in Q4 2023- -Held Type-B CMC Meeting with U.S. Food and Drug Administration (FDA) Regarding Pathway Towards Biologics Licen...

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial resul...

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company...

-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise- -Capricor to Receive an Upfront Payment of $12 Million, Additional Potential Milestone Payments of up to $89 Million as well as Meanin...

Toronto, Ontario--(Newsfile Corp. - February 1, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that it has entered into a binding option agreement dated January 31 st , 2023 (the " Option Agreement ") setting out the terms of an option to acq...

Capricor Therapeutics ( NASDAQ: CAPR ) reported 18-month results from its ongoing HOPE-2 open label extension (OLE) study in patients with later-stage Duchenne muscular dystrophy (DMD). DMD is genetic disorder characterized by progressive muscle degeneration and weakness due to the al...

-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchenne Muscular Dystrophy (DMD)- -Capricor to...